In a highdose semaglutide trial (7.2 mg weekly), participants lost about 20.7% of body weight in 72 weeks, with a substantial portion achieving up to 25% weight loss
Glucagon-like peptide-1 excites pancreas-projecting preganglionic vagal motoneurons
Additionally, companies are focusing on differentiating weight loss results in terms of muscle versus fat loss, with those showing minimal muscle loss likely to outperform
All these trials were designed to evaluate the primary outcome of 3-MACE defined as cardiovascular death, nonfatal myocardial infarct, and nonfatal stroke, except for the ELIXA trial of exenatide ER, which included hospitalization for unstable angina as an additional component of the 4-MACE composite outcomes
Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program